Kineta Revenue and Competitors
Estimated Revenue & Valuation
- Kineta's estimated annual revenue is currently $2.9M per year.
- Kineta's estimated revenue per employee is $77,500
- Kineta's total funding is $51.1M.
Employee Data
- Kineta has 37 Employees.
- Kineta grew their employee count by 0% last year.
Kineta's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Director | Reveal Email/Phone |
3 | Director Legal and Operations | Reveal Email/Phone |
4 | Chief Scientific Officer | Reveal Email/Phone |
5 | President | Reveal Email/Phone |
Kineta Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Kineta?
Kineta Inc. was formed in December 2007 by a group of scientists who are globally recognized for several breakthrough discoveries about the human immune system and the body’s reaction to the Hepatitis C virus. Through Kineta, our pioneering team is dedicated to further study of innate immunity with an aggressive strategy to develop early stage programs for powerful new antiviral and immune modulating drugs. We believe our unique approach will yield a new class of drugs to respond to diseases caused by viruses such as, Influenza, Hepatitis C and West Nile virus: diseases that afflict millions of people. This novel field of research is also applicable to dozens of autoimmune diseases. We believe in our science and our ability to improve lives around the world.
keywords:N/A
$51.1M
Total Funding
37
Number of Employees
$2.9M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kineta News
West Nile Virus Infections Medicine Market Size, Scope And Forecast | Leading Players CEL-SCI Corp, Fab'entech SA, Hemispherx Biopharma Inc, Kineta Inc,...
Kineta is developing fully human anti-CD27 agonist antibodies for the treatment of blood cancers and solid tumors. "Kineta's anti-CD27 program...
SEATTLE, March 21, 2022 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel...
SEATTLE, Aug. 10, 2021 /PRNewswire/ -- Kineta Inc, through its subsidiary Kineta Chronic Pain LLC, announced today that the company has received Patent No. 11,014,970 for Modifications and Uses of Conotoxin Peptides from the U.S. Patent and Trademark Office ("USPTO") related to KCP506, the com ...
SEATTLE, July 27, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (F ...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.6M | 37 | -36% | $197.5M |
#2 | $4.3M | 37 | 3% | N/A |
#3 | $7.5M | 37 | 6% | N/A |
#4 | $4.3M | 37 | 12% | N/A |
#5 | $4.3M | 37 | N/A | N/A |